

THE AMERICAN JOURNAL OF MANAGED CARE®

Publishing Staff

Senior Vice President
of Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Tara Petersen

Project Director

Christina Doong

Quality Assurance Editor

David Allikas

Associate Editor

Jeanne Linke

Design Director

Charles Lebeda

Associate Publisher

Andrew Colon

Director of Sales

Sara Stewart

National Account Managers

Gabrielle Consola

Michael Costella

Corporate

Chairman and CEO

Mike Hennessy

Vice Chairman

Jack Lepping

President

Tighe Blazier

Chief Financial Officer

Neil Glasser, CPA/CFE

President, Managed Markets

Brian Haug

Executive Vice President
and General Manager

John Maglione

Vice President of Human Resources

Rich Weisman

Vice President, Executive Creative
Director

Jeff Brown

Vice President of Education

David Heckard

Copyright © 2014 by Managed Care
& Healthcare Communications, LLC

December 2014 – Vol. 20, No. 13, Sup.

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

Table of Contents

Participating Faculty

S294

Report

- Diabetes-Related Quality Measure Attainment:
Canagliflozin Versus Sitagliptin Based on a
Pooled Analysis of 2 Clinical Trials

S296

**Robert A. Bailey, MD; Ujjwala Vijapurkar, PhD;
Gary E. Meininger, MD; Marcia F.T. Rupnow, PhD;
and Lawrence Blonde, MD**



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ A533

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

This supplement was supported by **Janssen Pharmaceuticals, Inc.**

This analysis was funded by Janssen Scientific Affairs, LLC. Editorial support was provided by Bilge Yoruk, PhD, of Excerpta Medica, and was funded by Janssen Scientific Affairs, LLC.

...

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Diabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials

This supplement to *The American Journal of Managed Care* describes the results of a post hoc analysis designed to evaluate attainment of diabetes-related quality measures with canagliflozin 100 mg, canagliflozin 300 mg, and sitagliptin 100 mg in patients with type 2 diabetes mellitus. This information may be relevant to stakeholders increasingly focused on quality measures and population health management, such as payers, healthcare delivery organizations, and clinicians.

■ Faculty

Robert A. Bailey, MD

Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey

Lawrence Blonde, MD

Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes, and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana

Gary E. Meininger, MD

Vice President, Franchise Medical Leader
Janssen Research and Development, LLC
Raritan, New Jersey

Marcia F.T. Rupnow, PhD

Senior Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey

Ujjwala Vijapurkar, PhD

Associate Director
Janssen Research and Development, LLC
Raritan, New Jersey

■ Faculty Disclosures

These faculty report relationships with the following organizations:

Robert A. Bailey, MD

Employment:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Lawrence Blonde, MD

Grants:

Eli Lilly and Company, Novo Nordisk, and sanofi-aventis

Honoraria:

AstraZeneca, Janssen Pharmaceuticals, Inc, Merck & Co, Inc, Novo Nordisk, Quest Diagnostics, and sanofi-aventis

Gary E. Meininger, MD

Employment:

Janssen Research and Development, LLC

Stock ownership:

Johnson & Johnson

Marcia F. T. Rupnow, PhD

Employment:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Ujjwala Vijapurkar, PhD

Employment:

Janssen Research and Development, LLC

Stock ownership:

Johnson & Johnson

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

■ SUPPLEMENT POLICY STATEMENT ■

Standards for Supplements to *The American Journal of Managed Care*

All supplements to *The American Journal of Managed Care* are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All *Journal* supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to *The American Journal of Managed Care* will:

- I. Be reviewed by at least one independent expert from a recognized academic medical institution.
- II. Disclose the source of funding in at least one prominent place.
- III. Disclose any existence of financial interests of supplement contributors to the funding organization.
- IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
- V. Be up-to-date, reflecting the current (as of date of publication) standard of care.
- VI. Be visually distinct from *The American Journal of Managed Care*.
- VII. Publish information that is substantially different in form and content from that of the accompanying edition of *The American Journal of Managed Care*.
- VIII. Prohibit excessive remuneration for contributors and reviewers.
- IX. Carry no advertising.

Publisher's Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.